Difference between revisions of "Autoimmune cytopenia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "/full " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "https://onlinelibrary.wiley.com/doi" to "https://doi.org") |
||
Line 28: | Line 28: | ||
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | !style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.1046/j.1365-2141.2001.03039.x Willis et al. 2001] |
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|style="background-color:#b5b5b5"|ORR: 71% | |style="background-color:#b5b5b5"|ORR: 71% | ||
Line 41: | Line 41: | ||
===References=== | ===References=== | ||
− | # Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [https:// | + | # Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [https://doi.org/10.1046/j.1365-2141.2001.03039.x link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11564082 PubMed] |
==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}== | ==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}== |
Revision as of 00:33, 17 September 2022
2 regimens on this page
2 variants on this page
|
This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.
Guidelines
"How I Treat"
- 2022: Porpaczy & Jäger How I manage autoimmune cytopenias in patients with lymphoid cancer
Relapsed or refractory
Alemtuzumab monotherapy
Regimen
Study | Evidence | Efficacy |
---|---|---|
Willis et al. 2001 | Phase 2 | ORR: 71% |
Immunosuppressive therapy
- Alemtuzumab (Campath) as follows:
- Test dose: 1 mg IV over 60 minutes once
- Days 1 to 10: 10 mg IV over 4 hours once per day
10-day course
References
- Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains dosing details in manuscript PubMed
Sirolimus monotherapy
Regimen
Study | Evidence | Efficacy |
---|---|---|
Bride et al. 2015 | Phase 2 | Durable CR observed in patients with ALPS |
Immunosuppressive therapy
- Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
- See manuscript for recommended dose adjustments
6-month course, extended for those with a favorable response
References
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains dosing details in abstract PubMed